Institute of Science and Technology Austria-based cell therapy startup Sarcura has closed a €2.5 million seed financing round. Investors include the Austrian Seed fund IST Cube, the Spanish VC firm Nina Capital and the Swedish investment company Axilium Capital, reports der brutkasten.
Founded in 2019 by Franz Emminger, Daniela Buchmayr, Erwin Gorjup, and Martin Fischlechner, Sarcura develops a machine platform for the large scale, GMP manufacturing of personalized cell therapy. Such therapies are based on semiconductor technology that enables bringing bioprocess control to the cellular level and used for patient cancer treatments. As the company says, its target is to scale global manufacturing capacity of these life-saving, cost-effective and safe solutions.
“With this new financing we can accelerate the development of our first product, a GMP cell sorter with the integrated real-time process and quality control,” Buchmayr, CEO of Sarcura, told about the startup’s further plans.
